🚀 GenSci128 Receives Orphan Drug Designation for Pancreatic Cancer Treatment
#GenSci128 #OrphanDrugDesignation #PancreaticCancer #ChangchunHighTech #FDA #OrphanDrugStatus #MarketExclusivity #TaxCredits #DrugDevelopment #GeneSciencePharmaceuticals
Changchun High-Tech announced that its subsidiary, Changchun GeneScience Pharmaceuticals Co., Ltd., has received notification from the U.S. Food and Drug Administration granting orphan drug designation to GenSci128 for the treatment of pancreatic cancer. According to Jin10, this designation is a significant step for the company in advancing its efforts to address this challenging disease. The orphan drug status is expected to provide certain benefits, including market exclusivity and potential tax credits, which could aid in the development and commercialization of GenSci128.#GenSci128 #OrphanDrugDesignation #PancreaticCancer #ChangchunHighTech #FDA #OrphanDrugStatus #MarketExclusivity #TaxCredits #DrugDevelopment #GeneSciencePharmaceuticals
🚀 Changchun High-tech Subsidiary Receives FDA Orphan Drug Designation for GenSci128, Targeting Gastric Cancer
#ChangchunHighTech #GenSciPharmaceuticals #FDA #OrphanDrugDesignation #GenSci128 #GastricCancer #TP53Y220C #CancerTreatment #Pharmaceuticals #FDAApproval #Oncology
Changchun High-tech announced that its subsidiary, GenSci Pharmaceuticals, has received notification from the FDA granting orphan drug designation (ODD) for GenSci128, aimed at treating gastric cancer. According to Jin10, GenSci128 is classified as a new chemical drug under category 1 for therapeutic use and falls under the U.S. new drug registration category '505b1.' It is a selective reactivator targeting the TP53 Y220C mutation, intended for treating locally advanced or metastatic solid tumors carrying the TP53 Y220C mutation, including pancreatic cancer, gastric cancer, ovarian cancer, breast cancer, and colorectal cancer.#ChangchunHighTech #GenSciPharmaceuticals #FDA #OrphanDrugDesignation #GenSci128 #GastricCancer #TP53Y220C #CancerTreatment #Pharmaceuticals #FDAApproval #Oncology